NCT06007937 2026-02-05
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
Clinical Trials
9 trialsNCT03909334 2025-10-20
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Hoosier Cancer Research Network
Phase 2 Active not recruiting
NCT02711553 2025-08-03
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company
Phase 2 Active not recruiting
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT03921671 2024-05-29
RELEVENT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT02572687 2021-01-20
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
Eli Lilly and Company
Phase 1 Completed
NCT02831491 2020-06-09
A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Withdrawn
NCT00917384 2019-09-25
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
Eli Lilly and Company
Phase 3 Completed
NCT01017731 2015-06-10
Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
Eli Lilly and Company
Phase 2 Completed